Alzheimer's Disease

Neurology and Clinical Neuroscience: Text with CD-ROM

Volumn , Issue , 2006, Pages 846-858

  Boughey, John G F ^a   Graff Radford, Neill R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34247112659     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03354-1.50069-9     Document Type: Chapter

References (65)

1. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1154-1156.
2. Golde TE Alzheimer disease therapy: can the amyloid cascade be halted?. J Clin Invest 2003, 111:11-18.
3. Hardy J Toward Alzheimer therapies based on genetic knowledge. Annu Rev Med 2004, 55:15-25.
4. Schenk D, Hagen M, Seubert P Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 2004, 16:599-606.
5. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000, 54:S10-S15.
6. Bachman DL, Wolf PA, Linn RT, et al. Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study. Neurology 1993, 43:515-519.
7. Mayeux R Epidemiology of neurodegeneration. Annu Rev Neurosci 2003, 26:81-104.
8. Alzheimer A Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift Fur Pschiatrie und phychish-Gerichtliche Medizin (Berlin) 1907, 64:146-148.
9. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003, 60:1119-1122.
10. Small G, Rabins P, Barry P, et al. Diagnosis and treatment of Alzheimer's disease and related disorders. Consensus Statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997, 278:1363-1371.
11. Brookmeyer R, Gray S, Kawas C Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998, 88:1337-1342.
12. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E geno-type and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium [Comment]. JAMA 1997, 278:1349-1356.
13. Graff-Radford NR, Green RC, Go RC, et al. Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch Neurol 2002, 59:594-600.
14. Ertekin-Taner N, Graff-Radford N, Younkin LH, et al. Linkage of plasma Aβ42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 2000, 290:2303-2304.
15. Glenner GG, Wong CW Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984, 122:1131-1135.
16. Kanai M, Matsubara E, Isoe KEA Longitudinal study of cerebrospinal fluid levels of tau, Ab1-40, and Ab1-42(3) in Alzheimer's disease: a study in Japan. Ann Neurol 1998, 44:17-26.
17. Gravina SA, Ho L, Eckman CB, et al. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 1995, 270:7013-7016.
18. Arnold SE, Hyman BT, Flory J, et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1991, 1:103-116.
19. Crystal H, Dickson D, Fuld P, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988, 38:1682-1687.
20. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001, 293:1487-1491.
21. Fillenbaum GG, Huber MS, Beekly D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XIII. Obtaining autopsy in Alzheimer's disease. Neurology 1996, 46:142-145.
22. Khachaturian Z Diagnosis of Alzheimer's disease. Arch Neurol 1985, 42:1097-1105.
23. Newell KL, Hyman BT, Growdon JH, et al. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol 1999, 58:1147-1155.
24. Mirra S, Gearling M, McKeel D, et al. Interlaboratory comparison of neuropathology assessments in Alzheimer's disease: a study of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD). J Neuropathol Exp Neurol 1994, 53:303-315.
25. Kokmen E, Naessens J, Offord K A Short Test of Mental Status: description and preliminary results. Mayo Clin Proc 1987, 62:281-288.
26. Becker P, Feussner J, Mulrow C, et al. The role of lumbar puncture in the evaluation of dementia: the Durhar Veterans Administration/Duke University Study. J Am Geriatr Soc 1985, 33:392-396.
27. Hammestrom D, Zimmer B The role of lumbar puncture in the evaluation of dementia: the University of Pittsburgh Study. J Am Geriatr Soc 1985, 33:397-400.
28. Consensus Report of the Working Group on "Molecular and Biochemical Markers of Alzheimer's disease." The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998, 19:109-116. [Erratum in Neurobiol Aging 1998; 19:285].
29. Blennow K, Hampel H CSF markers for incipient Alzheimer's disease [Review]. Lancet Neurol 2003, 2:605-613.
30. Wahlund LO, Julin P, Johansson SE, et al. Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. J Neurol Neurosurg Psychiatry 2000, 69:630-635.
31. Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000, 41:1920-1928.
32. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319.
33. Dubinsky RM, Stein AC, Lyons K Practice parameter: risk of driving and Alzheimer's disease (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology [Review]. Neurology 2000, 54:2205-2211.
34. Sink KM, Holden KF, Yaffe K Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence [Review]. JAMA 2005, 293:596-608.
35. Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005, 330:874.
36. Mayeux R Apolipoprotein E, Alzheimer disease, and African Americans [Comment]. Arch Neurol 2003, 60:161-163.
37. Green RC, Cupples LA, Go R, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 2002, 287:329-336.
38. Goate A, Chartier-Harlin M, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's diseases. Nature 1991, 349:704-706.
39. Levy-Lehad E, Wijsman E, Nemens EEA A familial Alzheimer's disease locus on chromosome 1. Science 1995, 269:970-973.
40. St.George-Hyslop P, Haines J, Rogaev E, et al. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nat Genet 1992, 2:330-334.
41. Pericak-Vance M, Bebout J, Gaskell P, et al. Linkage studies in familial Alzheimer's disease: evidence for chromosome 19 linkage. Am J Hum Genet 1991, 48:1034-1050.
42. Kamboh MI Molecular genetics of late-onset Alzheimer's disease. Ann Hum Genet 2004, 68:381-404.
43. Schupf N, Kapell D, Nightingale B, et al. Specificity of the five-fold increase in AD in mothers of adults with Down syndrome. Neurology 2001, 57:979-984.
44. Andersen K, Launer LJ, Dewey ME, et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology 1999, 53:1992-1997.
45. Guo Z, Cupples LA, Kurz A, et al. Head injury and the risk of AD in the MIRAGE study. Neurology 2000, 54:1316-1323.
46. Plassman BL, Havlik RJ, Steffens DC, et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology 2000, 55:1158-1166.
47. Casserly I, Topol E Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 2004, 363:1139-1146.
48. Snowdon DA, Kemper SJ, Mortimer JA, et al. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. JAMA 1996, 275:528-532.
49. Verghese J, Lipton RB, Katz MJ, et al. Leisure activities and the risk of dementia in the elderly. N Engl J Med 2003, 348:2508-2516.
50. Szekely C, Thorne J, Zandi PP, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004, 23:159-169.
51. Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000, 57:1439-1443.
52. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289:2651-2662.
53. Yaffe K, Sawaya G, Lieberburg I, et al. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998, 279:688-695.
54. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002, 346:476-483.
55. Morris MC, Evans DA, Bienias JL, et al. Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline. J Neurol Neurosurg Psychiatry 2004, 75:1093-1099.
56. Yaffe K, Barnes D, Nevitt M, et al. A prospective study of physical activity and cognitive decline in elderly women: women who walk [Comment]. Arch Intern Med 2001, 161:1703-1708.
57. Orgogozo JM, Dartigues JF, Lafont S, et al. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol 1997, 153:185-192.
58. Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease [Comment]. Arch Neurol 2003, 60:940-946.
59. Morris MC, Evans DA, Bienias JL, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002, 287:3230-3237.
60. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996, 2:864-870.
61. Graff-Radford N, Eckman C, O'Brien P, et al. Plasma amyloid β protein (Aβ) in Down's syndrome (DS): implications for Alzheimer's disease. Neurology 1997, 47:A378.
62. Schupf N, Patel B, Silverman W, et al. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett 2001, 301:199-203.
63. Tokuda T, Fukushima T, Ikeda S, et al. Plasma levels of amyloid β proteins Ab1-40 and Ab1-42(43) are elevated in Down's syndrome. Ann Neurol 1997, 41:271-273.
64. Gearing M, Mori H, Mirra S Aβ-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann Neurol 1996, 39:395-399.
65. Graff-Radford N, Eckman C, Hutton M, et al. Plasma amyloid (Aβ) levels in relatives of Alzheimer's disease patients. Neurology 1998, 48:A314.